Cargando…
Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)
BACKGROUND: Nocturia is a common urinary symptom of multiple sclerosis (MS) which can affect quality of life (QoL) adversely. Melatonin is a hormone known to regulate circadian rhythm and reduce smooth muscle activity such as in the bladder. There is limited evidence supporting use of melatonin to a...
Autores principales: | Drake, Marcus J., Canham, Luke, Cotterill, Nikki, Delgado, Debbie, Homewood, Jenny, Inglis, Kirsty, Johnson, Lyndsey, Kisanga, Mary C., Owen, Denise, White, Paul, Cottrell, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091206/ https://www.ncbi.nlm.nih.gov/pubmed/30081859 http://dx.doi.org/10.1186/s12883-018-1114-4 |
Ejemplares similares
-
Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)
por: Delgado, D., et al.
Publicado: (2017) -
What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT
por: Khan, Rafiyah, et al.
Publicado: (2018) -
A practical approach to the management of nocturia
por: Oelke, Matthias, et al.
Publicado: (2017) -
Pharmacotherapy for Nocturia
por: Andersson, Karl-Erik, et al.
Publicado: (2018) -
The potential of visual physiology: An instrument with a place in MS translation
por: Canham, L.J.W., et al.
Publicado: (2019)